Latest filings (excl ownership)
6-K
Notice of Meeting and Record Date
26 Apr 24
6-K
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
2 Apr 24
20-F
2023 FY
Annual report (foreign)
1 Apr 24
6-K
Material Change Report
26 Feb 24
6-K
Cardiol Therapeutics Completes Patient Enrollment in its Phase II
21 Feb 24
6-K
Cardiol Therapeutics Granted Orphan Drug Designation for its
15 Feb 24
6-K
Current report (foreign)
24 Jan 24
6-K
Cardiol Therapeutics Announces it has Exceeded
9 Jan 24
6-K
MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024
5 Dec 23
6-K
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group
16 Nov 23
6-K
Current report (foreign)
14 Nov 23
6-K
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its
1 Nov 23
6-K
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
20 Oct 23
6-K
Material Change Report
11 Oct 23
6-K
Data Presented at the Heart Failure Society of America Annual Scientific Meeting 2023
10 Oct 23
6-K
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
26 Sep 23
6-K
Material Change Report
20 Sep 23
6-K
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule
19 Sep 23
6-K
Current report (foreign)
10 Aug 23
6-K
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
9 Aug 23
6-K
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
8 Aug 23
6-K
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
29 Jun 23
6-K
Current report (foreign)
27 Jun 23
6-K
Current report (foreign)
18 May 23
6-K
Condensed Interim Consolidated Statements of Financial Position
15 May 23
6-K
Cardiol Therapeutics Announces Year-End 2022 Update on Operations
29 Mar 23
20-F
2022 FY
Annual report (foreign)
28 Mar 23
6-K
Current report (foreign)
7 Mar 23
6-K
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the
17 Jan 23
6-K
Current report (foreign)
12 Dec 22
6-K
Current report (foreign)
14 Nov 22
6-K
Current report (foreign)
10 Nov 22
6-K
Current report (foreign)
7 Nov 22
6-K
Material Change Report
26 Oct 22
6-K
Current report (foreign)
25 Oct 22
6-K
Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022
3 Oct 22
6-K
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the
28 Sep 22
6-K
Current report (foreign)
10 Aug 22
6-K
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis
3 Aug 22
6-K
Cardiol Therapeutics Reports Results of
29 Jun 22